NCT00134199View on ClinicalTrials.gov

A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

282

Participants

Timeline

Start Date

March 31, 2005

Study Completion Date

November 30, 2005

Conditions
Obesity
Interventions
DRUG

CP-945,598

DRUG

sibutramine

Trial Locations (15)

10021

Pfizer Investigational Site, New York

28211

Pfizer Investigational Site, Charlotte

32809

Pfizer Investigational Site, Orlando

33761

Pfizer Investigational Site, Clearwater

34741

Pfizer Investigational Site, Kissimmee

37203

Pfizer Investigational Site, Nashville

40213

Pfizer Investigational Site, Louisville

40509

Pfizer Investigational Site, Lexington

70808

Pfizer Investigational Site, Baton Rouge

75231

Pfizer Investigational Site, Dallas

75247

Pfizer Investigational Site, Dallas

78229

Pfizer Investigational Site, San Antonio

98403

Pfizer Investigational Site, Tacoma

98418

Pfizer Investigational Site, Tacoma

01757

Pfizer Investigational Site, Milford

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY